<code id='0C9FB25597'></code><style id='0C9FB25597'></style>
    • <acronym id='0C9FB25597'></acronym>
      <center id='0C9FB25597'><center id='0C9FB25597'><tfoot id='0C9FB25597'></tfoot></center><abbr id='0C9FB25597'><dir id='0C9FB25597'><tfoot id='0C9FB25597'></tfoot><noframes id='0C9FB25597'>

    • <optgroup id='0C9FB25597'><strike id='0C9FB25597'><sup id='0C9FB25597'></sup></strike><code id='0C9FB25597'></code></optgroup>
        1. <b id='0C9FB25597'><label id='0C9FB25597'><select id='0C9FB25597'><dt id='0C9FB25597'><span id='0C9FB25597'></span></dt></select></label></b><u id='0C9FB25597'></u>
          <i id='0C9FB25597'><strike id='0C9FB25597'><tt id='0C9FB25597'><pre id='0C9FB25597'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:focus    - browse:7826
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot